药代-话题@MedSci

#药代#

158篇内容 | 3051人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1666691, encodeId=7d51166669164, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医院接待药代新规，这些行为全部禁止, objectType=article, longId=138730, objectId=6b85138e30b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b85138e30b6, replyNumber=0, likeNumber=65, createdTime=2018-09-27, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b85138e30b6, moduleTitle=医院接待药代新规，这些行为全部禁止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b85138e30b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666687, encodeId=18b3166668e71, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医保大控费后，药代的机会却来了, objectType=article, longId=133493, objectId=fb841334930d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb841334930d, replyNumber=0, likeNumber=61, createdTime=2018-10-05, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb841334930d, moduleTitle=医保大控费后，药代的机会却来了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb841334930d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666706, encodeId=a4171666e0685, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=国家带量采购，冲击药代！, objectType=article, longId=149870, objectId=f4111498e096, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4111498e096, replyNumber=0, likeNumber=136, createdTime=2019-01-06, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4111498e096, moduleTitle=国家带量采购，冲击药代！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4111498e096)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666680, encodeId=8549166668082, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医药代表的7大特长，看完都是泪, objectType=article, longId=128443, objectId=91d0128443de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91d0128443de, replyNumber=0, likeNumber=0, createdTime=2018-11-30, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91d0128443de, moduleTitle=医药代表的7大特长，看完都是泪, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91d0128443de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666709, encodeId=b01d1666e09a9, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征, objectType=article, longId=152526, objectId=ad2715252671, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad2715252671, replyNumber=0, likeNumber=79, createdTime=2018-12-21, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad2715252671, moduleTitle=Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad2715252671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666696, encodeId=134d1666696b7, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Nature Materials：吃药代替手术，治疗II型糖尿病, objectType=article, longId=140831, objectId=8efc14083163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8efc14083163, replyNumber=0, likeNumber=69, createdTime=2019-03-14, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8efc14083163, moduleTitle=Nature Materials：吃药代替手术，治疗II型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8efc14083163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666708, encodeId=bf2d1666e087f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=全国药代大检查，风暴来了！, objectType=article, longId=150967, objectId=ec1d15096ebc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec1d15096ebc, replyNumber=0, likeNumber=54, createdTime=2019-01-08, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec1d15096ebc, moduleTitle=全国药代大检查，风暴来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec1d15096ebc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666701, encodeId=c00d1666e0111, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=广州三甲医院新规，严格限制医药代表拜访，如有发现直接现场执法, objectType=article, longId=146490, objectId=673514649077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=673514649077, replyNumber=0, likeNumber=95, createdTime=2019-04-09, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=673514649077, moduleTitle=广州三甲医院新规，严格限制医药代表拜访，如有发现直接现场执法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=673514649077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666688, encodeId=58841666688b0, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Bone Joint J：硫酸钙载万古霉素的体外药代动力学研究, objectType=article, longId=134850, objectId=70c3134850f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70c3134850f1, replyNumber=0, likeNumber=53, createdTime=2018-11-24, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70c3134850f1, moduleTitle=Bone Joint J：硫酸钙载万古霉素的体外药代动力学研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70c3134850f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666685, encodeId=981716666857a, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=CLIN CANCER RES：恩杂鲁胺对卡巴他赛药代动力学的影响, objectType=article, longId=130594, objectId=e35a13059432, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e35a13059432, replyNumber=0, likeNumber=68, createdTime=2018-08-15, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e35a13059432, moduleTitle=CLIN CANCER RES：恩杂鲁胺对卡巴他赛药代动力学的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e35a13059432)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666703, encodeId=36cf1666e038c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=上海部队医院严查医药代表！, objectType=article, longId=147176, objectId=d41914e176b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d41914e176b6, replyNumber=0, likeNumber=76, createdTime=2019-03-04, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d41914e176b6, moduleTitle=上海部队医院严查医药代表！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d41914e176b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666694, encodeId=92ff1666694c6, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=药代还能存在多久？北京“新政”：医生彻底与药代划清界限！, objectType=article, longId=140183, objectId=bee514018372, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee514018372, replyNumber=0, likeNumber=97, createdTime=2019-03-23, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee514018372, moduleTitle=药代还能存在多久？北京“新政”：医生彻底与药代划清界限！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee514018372)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666673, encodeId=db2816666e3c8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=备案制下的百万药代还有这些新出路（上篇）, objectType=article, longId=119883, objectId=8e9d119883d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e9d119883d8, replyNumber=0, likeNumber=80, createdTime=2018-07-07, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e9d119883d8, moduleTitle=备案制下的百万药代还有这些新出路（上篇）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e9d119883d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666676, encodeId=ef9f16666e6d9, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=为什么一个医药代表备案制就让医药行业震惊成这样？, objectType=article, longId=124832, objectId=a591124832d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a591124832d5, replyNumber=0, likeNumber=67, createdTime=2018-02-28, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a591124832d5, moduleTitle=为什么一个医药代表备案制就让医药行业震惊成这样？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a591124832d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666682, encodeId=b8f9166668278, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=网上处方药代购将被7*24全天候监控，天猫、京东、论坛、贴吧、QQ、微信、微博全部在内！, objectType=article, longId=128912, objectId=c2f212891298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2f212891298, replyNumber=0, likeNumber=99, createdTime=2018-07-15, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2f212891298, moduleTitle=网上处方药代购将被7*24全天候监控，天猫、京东、论坛、贴吧、QQ、微信、微博全部在内！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2f212891298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666674, encodeId=3c3f16666e4de, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果, objectType=article, longId=122554, objectId=1415122554e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1415122554e2, replyNumber=0, likeNumber=92, createdTime=2018-03-08, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1415122554e2, moduleTitle=Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1415122554e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666678, encodeId=963b16666e8bc, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Pharmaceut Res:茚地那韦部分通过抑制多药和毒素排出蛋白1（MATE1）改变拉米夫定的药代动力学, objectType=article, longId=125692, objectId=336a1256926c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=336a1256926c, replyNumber=0, likeNumber=64, createdTime=2018-07-18, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=336a1256926c, moduleTitle=Pharmaceut Res:茚地那韦部分通过抑制多药和毒素排出蛋白1（MATE1）改变拉米夫定的药代动力学, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=336a1256926c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666697, encodeId=f92c166669e16, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=三甲医院通知：药代禁止伪装、须出无罪证明, objectType=article, longId=141536, objectId=a853141536d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a853141536d8, replyNumber=0, likeNumber=79, createdTime=2018-10-24, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a853141536d8, moduleTitle=三甲医院通知：药代禁止伪装、须出无罪证明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a853141536d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666683, encodeId=9bb61666683d4, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Crit Care：美罗培南在脓毒症患者持续低效透析中的药代动力学研究！, objectType=article, longId=129120, objectId=282b129120f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282b129120f4, replyNumber=0, likeNumber=74, createdTime=2018-09-28, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282b129120f4, moduleTitle=Crit Care：美罗培南在脓毒症患者持续低效透析中的药代动力学研究！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282b129120f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666670, encodeId=bdc416666e0aa, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=西安：医药代表要登记备案, objectType=article, longId=116048, objectId=378b1160480d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=378b1160480d, replyNumber=0, likeNumber=88, createdTime=2017-12-17, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=378b1160480d, moduleTitle=西安：医药代表要登记备案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=378b1160480d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

药代

2020-05-29

fengyqf (审核中...)

前往app查看评论内容

#药代#

医院接待药代新规，这些行为全部禁止

2018-09-27

fengyqf (审核中...)

前往app查看评论内容

#药代#

医保大控费后，药代的机会却来了

2018-10-05

fengyqf (审核中...)

前往app查看评论内容

#药代#

国家带量采购，冲击药代！

2019-01-06

fengyqf (审核中...)

前往app查看评论内容

#药代#

医药代表的7大特长，看完都是泪

2018-11-30

fengyqf (审核中...)

前往app查看评论内容

#药代#

Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征

2018-12-21

fengyqf (审核中...)

前往app查看评论内容

#药代#

Nature Materials：吃药代替手术，治疗II型糖尿病

2019-03-14

fengyqf (审核中...)

前往app查看评论内容

#药代#

全国药代大检查，风暴来了！

2019-01-08

fengyqf (审核中...)

前往app查看评论内容

#药代#

广州三甲医院新规，严格限制医药代表拜访，如有发现直接现场执法

2019-04-09

fengyqf (审核中...)

前往app查看评论内容

#药代#

Bone Joint J：硫酸钙载万古霉素的体外药代动力学研究

2018-11-24

fengyqf (审核中...)

前往app查看评论内容

#药代#

CLIN CANCER RES：恩杂鲁胺对卡巴他赛药代动力学的影响

2018-08-15

fengyqf (审核中...)

前往app查看评论内容

#药代#

上海部队医院严查医药代表！

2019-03-04

fengyqf (审核中...)

前往app查看评论内容

#药代#

药代还能存在多久？北京“新政”：医生彻底与药代划清界限！

2019-03-23

fengyqf (审核中...)

前往app查看评论内容

#药代#

备案制下的百万药代还有这些新出路（上篇）

2018-07-07

fengyqf (审核中...)

前往app查看评论内容

#药代#

为什么一个医药代表备案制就让医药行业震惊成这样？

2018-02-28

fengyqf (审核中...)

前往app查看评论内容

#药代#

网上处方药代购将被7*24全天候监控，天猫、京东、论坛、贴吧、QQ、微信、微博全部在内！

2018-07-15

fengyqf (审核中...)

前往app查看评论内容

#药代#

Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果

2018-03-08

fengyqf (审核中...)

前往app查看评论内容

#药代#

Pharmaceut Res:茚地那韦部分通过抑制多药和毒素排出蛋白1（MATE1）改变拉米夫定的药代动力学

2018-07-18

fengyqf (审核中...)

前往app查看评论内容

#药代#

三甲医院通知：药代禁止伪装、须出无罪证明

2018-10-24

fengyqf (审核中...)

前往app查看评论内容

#药代#

Crit Care：美罗培南在脓毒症患者持续低效透析中的药代动力学研究！

2018-09-28

fengyqf (审核中...)

前往app查看评论内容

#药代#

西安：医药代表要登记备案

2017-12-17

科室
- - 订阅+
  - 更多科室
工具
服务